Paliperidone Palmitate 3-Month Formulation
Psychotic Disorders
Consorcio Centro de Investigación Biomédica en Red (CIBER)Phase 4 / ApprovedActive
BBB
76/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 72/ 100
- Competitive Position
- 81/ 100
Competitive context
36 Active assets in the Psychotic Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Risperdal Northwell Health | Phase 4 | BBB |
Olanzapine Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
Asenapine Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec | Phase 4 | BBB |
Haloperidol Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Phase 4 | BBB |
SIMVASTATIN Mclean Hospital | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Paliperidone Palmitate 3-Month Formulation is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →